Tafero EM 10 (Tenofovir Alafenamide & Emtricitabine)
Tafero EM , a combination tablet contains tenofovir Alafenamide fumarate and Emtricitabine is mainly indicated for the treatment of HIV-1 infection in adult’s patients.
DESCRIPTION
Classification: Anti-retroviral drug TAF and Emtricitabine are nucleotide reverse transcriptase inhibitor that involved in suppression of growth of HIV virus associated with AIDS
Tafero EM is a fixed dose combination drug, which contains two excellent components like tenofovir Alafenamide fumarate and Emtricitabine Tafero EM is a prescription medicine, used by the patients only under the knowledge of medical practitioner
INDICATION
Tafero EM , a combination tablet contains tenofovir Alafenamide fumarate and Emtricitabine is mainly indicated for the treatment of HIV-1 infection in adult’s patients.
MECHANISM OF ACTION
TAF
TAF is a novel ester prodrug of anti-retroviral tenofovir, and it is a nucleotide reverse transcriptase inhibitor After an oral administration, TAF is transformed into tenofovir Tenofovir (acyclic nucleoside phosphonate analog of adenosine 5 monophosphate) Tenofovir depletes DNA binding, there is a lack of 3 OH molecules (water molecules are responsible for phosphodiester bond linkage) By opposing the regular nucleotide for insertion into proviral DNA and blockade of formation of 5 to 3 phosphodiester linkage which is needed for DNA elongation Tenofovir leads to chain termination and block proviral DNA transcription
Emtricitabine
Emtricitabine is one of the components of Tafero EM; it exhibits its anti-retroviral activity by inhibiting reverse transcriptase, the enzyme which is responsible for transcript HIV RNA into new viral DNA. Emtricitabine is phosphorylated to Emtricitabine 5 phosphate with the help of cellular enzymes Emtricitabine 5 phosphates is HIV-1 reverse transcriptase inhibitor Emtricitabine 5 phosphates fight with deoxycytidine 5 triphosphate (natural substrate) and inserted into viral DNA causes chain termination
ADME PROPERTIES
ABSORPTION
Tafero EM ; the absorption of tenofovir is occur fastly and its Tmax is observed at 1 hour after administration; whereas Emtricitabine is absorbed rapidly and its mean bioavailability is 93%
DISTRIBUTION
The human plasma protein bound of Emtricitabine is very low less than 4% Tenofovir is highly bound to human plasma protein with the range of 80%
METABOLISM
TAF, is hydrolyzed into tenofovir within the cells, it is the major metabolite again phosphorylated into tenofovir diphosphate active metabolite Emtricitabine is metabolized minimally and it is found in urine as unchanged form
EXCRETION
The route of elimination mostly through urine The terminal half life of Emtricitabine is 10 hours The terminal half life period of tenofovir is 0.51 hour
DOSAGE MANAGEMENT
DOSAGE AND ADMINISTRATION
The prescribed dose of Tafero EM in the condition of HIV-1 infection in adults is, one tablet should be taken once daily with or without food. In Pre-exposure Prophylaxis: uninfected adults should take one tablet orally as a single dose.
SIDE EFFECTS
GENERAL
Diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal drms
METABOLIC
Increased fasting cholesterol, decreased phosphorus, increased fasting triglycerides, altered serum glucose, weight loss, hyperglycemia, increased alkaline phosphatase, lactic acidosis severe hepatomegaly
HEPATIC
Increased AST and ALT, hepatic steatosis, lactic acidosis, increased bilirubin, severe acute exacerbation of hepatitis B
BLOOD
Decreased neutrophils and hemoglobulin
RESPIRATORY
Pharyngitis, sinusitis, upper respiratory tract infection, Nasopharyngitis, increased cough, pneumonia, rhinitis
GASTROINTESTINAL
Increased serum amylase, abdominal pain, pancreatitis, increased serum lipase
PSYCHIATRIC
Depression, insomnia, anxiety
NERVE SYSTEM
Headache, somnolence, peripheral neuropathy
OTHERS
Fatigue, syphilis, pain, fever, asthenia, high vitamin D levels
SKIN
Rashes, skin discoloration, lipodystrophy, angioedema, sweating
GENITOURINARY
Proteinuria, urethritis, urinary tract infection, Hematuria, genital ulceration, anogenital warts Polyuria, glycosuria
IMMUNE
Immune reconstitution/reactivation syndrome, autoimmune disorders
HYPERSENSITIVITY
Allergic reaction
ENDOCRINE
High serum parathyroid hormones
PRECAUTION
Tafero EM should be used cautiously, during the therapy some of adverse effects occur; Immune reconstitution syndrome Lactic acidosis Hepatomegaly with steatosis Renal toxicity Acute or severe exacerbations of HBV occurs during discontinuation of anti-retroviral therapy Renal impairment
DRUG INTERACTION
Acyclovir-valaciclovir: increase the serum concentration of tenofovir Adefovir: decrease the therapeutic effect of tenofovir Amino glycosides: increase the serum concentration of tenofovir Carbamazepine: decrease the serum concentration of tenofovir Cidofovir: increase the serum concentration of tenofovir Cobicistat: may increase the toxic effects of tenofovir Diclofenac: may enhance the nephrotoxicity effect of tenofovir Fosphenytoin/phenytoin: decrease the serum concentration of tenofovir Lamivudine: increase toxic effects of Emtricitabine NSAIDS: increase the nephrotoxicity effect of tenofovir Orlistat: decrease the serum concentration of anti-retroviral drugs Oxcarbazepine, Phenobarbital, primidone, rifabutin, rifampin, rifapentine, st. Johns wort, tipranavir these are the drugs which involved in depletion of serum concentration of tenofovir
CONTRAINDICATIONS
Tafero EM should not be used in persons with unknown or positive 1 status. Tafero EM not used as monotherapy, it is used with other retroviral medicine. Hypersensitivity in lactation .
PREGNANCY & LACTATION
Pregnancy category: B Tafero EM should be used cautiously, it is recommended for limited number for pregnancy In case of any deformity, Tafero EM should not suggested for pregnancy condition or women who become pregnant Breast feeding is not recommended
STORAGE
Tafero EM tablet container should be stored below 30°C (86°F) Container should be keep away from moisture, heat and light
MISSED DOSE
If patient fail to take the dose of Tafero EM tablet, must consult with medical practitioner To avoid overdose toxicity problems, skipped the missed dose and follow the regular dosing schedule Do not take double dose
Пока нет комментариев